Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Nodality sales and marketing update

    Nodality Inc., South San Francisco, Calif. Business: Diagnostic Nodality launched its PathPro T cell receptor (TCR) and B cell receptor panels to measure signaling and compound activity in primary human cells. Nodality …

    Published on 6/29/2015
  • Quest Diagnostics sales and marketing update

    Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Diagnostic Quest launched laboratory-developed test QNatal Advanced to screen for chromosomal abnormalities in high-risk pregnancies by analyzing cell-free …

    Published on 6/29/2015
  • BioMarin sales and marketing update

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Business: Endocrine/Metabolic The Highly Specialised Technologies (HST) Evaluation Committee of the U.K.s NICE said it is minded not to recommend Vimizim …

    Published on 6/22/2015
  • Cancer Genetics sales and marketing update

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Diagnostic Cancer Genetics launched the Focus::Myeloid 54-biomarker panel in the U.S. to diagnose and determine prognosis for patients with myeloid cancers.

    Published on 6/22/2015
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Autoimmune The U.K.s NICE issued draft guidance recommending against Otezla apremilast from Celgene to treat moderate to severe chronic plaque psoriasis in adults who …

    Published on 6/22/2015
  • Courtagen Life Sciences sales and marketing update

    Courtagen Life Sciences Inc., Woburn, Mass. Business: Diagnostic Courtagen launched its rxSEEK epilepsy drug metabolism test worldwide, except New York state, to analyze specific liver enzyme genes to identify which …

    Published on 6/22/2015
  • Lundbeck, Takeda sales and marketing update

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology The U.K.s NICE issued draft guidance requesting information on Brintellix vortioxetine from H.…

    Published on 6/22/2015
  • Medivation, Astellas sales and marketing update

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer The U.K.s NICE issued draft guidance recommending against Xtandi enzalutamide from Astellas to treat …

    Published on 6/22/2015
  • Mylan, Gilead sales and marketing update

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Mylans Mylan Pharmaceuticals Pvt. Ltd. subsidiary launched Gileads Sovaldi sofosbuvir 400 mg tablets…

    Published on 6/22/2015
  • Quest Diagnostics sales and marketing update

    Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Diagnostic Quest launched its LeukoVantage genomic service test for the diagnosis, prognosis, monitoring and selecting of treatment for patients with myeloid …

    Published on 6/22/2015
  • Teva, Momenta, Novartis sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Autoimmune, Generics …

    Published on 6/22/2015
  • Veritas sales and marketing update

    Veritas Genetics, Danvers, Mass. Business: Diagnostic Veritas launched the myBRCA genetic screening test in the U.S., Europe and China to identify women with high risk of breast and ovarian cancer. The saliva-based test…

    Published on 6/22/2015
  • Actavis sales and marketing update

    Actavis plc (NYSE:ACT), Dublin, Ireland Business: Infectious Actavis launched Avycaz ceftazidime/avibactam in the U.S. to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract …

    Published on 6/15/2015
  • Bayer sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer The U.K.s NICE issued draft guidance recommending Xofigo radium-223 dichloride from Bayer to treat adults with castration-resistant prostate cancer (CRPC), …

    Published on 6/15/2015
  • Biogen, Genentech, Chugai, Nippon Shinyaku, Roche sales and marketing update

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Nippon Shinyaku Co. Ltd. (Tokyo:4516), Kyoto, Japan Roche (SIX:ROG; OTCQX…

    Published on 6/15/2015
  • Mylan sales and marketing update

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Infectious Mylans Mylan Pharmaceuticals Pvt. Ltd subsidiary launched MyHep, a generic version of 400 mg Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD, …

    Published on 6/15/2015
  • Vivus, Wal-Mart Stores Inc. sales and marketing update

    Vivus Inc. (NASDAQ:VVUS), Mountain View, Calif. Wal-Mart Stores Inc. (NYSE:WMT), Bentonville, Ark. Business: Endocrine/Metabolic Effective May 1, premium members of Wal-Marts Sams Club division pay lower out-of-pocket …

    Published on 6/15/2015
  • Actavis sales and marketing update

    Actavis plc (NYSE:ACT), Dublin, Ireland Business: Ophthalmic The U.K.s NICE issued a final appraisal determination (FAD) recommending Ozurdex dexamethasone intravitreal implant (SK-0503) from Actavis to treat diabetic …

    Published on 6/8/2015
  • Amplion sales and marketing update

    Amplion Inc., Bend, Ore. Business: Supply/Service Amplion launched the BiomarkerBase biomarker database. Amplion said BiomarkerBase includes validated biomarkers in clinical use as well as those in laboratory-developed …

    Published on 6/8/2015
  • Biomedica Medizinprodukte sales and marketing update

    Biomedica Medizinprodukte GmbH & Co. KG, Vienna, Austria Business: Renal Biomedica launched its FGF23 (C-terminal) Elisa assay in Europe to measure intact and C-terminal fragments of fibroblast growth factor 23 (FGF23) …

    Published on 6/8/2015
  • Boehringer Ingelheim sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer The German Institute for Quality and Efficiency in Health Care (IQWiG) said Vargatef nintedanib from Boehringer in combination with docetaxel has minor …

    Published on 6/8/2015
  • Bristol-Myers, J&J sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune The U.K.s NICE issued final guidance recommending Stelara ustekinumab from Johnson & Johnsons …

    Published on 6/8/2015
  • Bristol-Myers, Pfizer sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cardiovascular The U.K.s NICE issued final guidance recommending the use of Eliquis apixaban from Bristol-Myers and …

    Published on 6/8/2015
  • Cancer Genetics sales and marketing update

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Cancer Cancer Genetics launched its Hotspot sequencing panel in India and Asia. The panel assesses mutations in 50 genes associated with breast, colorectal,…

    Published on 6/8/2015
  • Genmab, Novartis sales and marketing update

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cancer The U.K.s NICE issued final guidance recommending Arzerra ofatumumab (HuMax-CD20) from …

    Published on 6/8/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993